Results for embolisering translation from Swedish to English

embolisering, terapeutisk
embolization

emboli (trombotisk embolisering)
embolism (thrombotic embolisation)

fettembolisering (embolisering av kolesterolkristaller)
fat embolisation (cholesterol crystal embolism), which may lead to corresponding consequences in the organs concerned

blödning emboli (trombotisk embolisering)
embolism (thrombotic embolisation)

blodproppar i blodkärlen (trombotisk embolisering)
− low blood pressure (hypotension) − irregular heart beat − chest pain (angina pectoris) − bleeding where the injection is given

riociguat ska undvikas hos patienter med allvarlig hemoptys i anamnesen eller som tidigare har genomgått bronkial arteriell embolisering.
riociguat should be avoided in patients with a history of serious haemoptysis or who have previously undergone bronchial arterial embolisation.

risken för allvarlig och dödlig blödning i luftvägarna kan öka ytterligare under behandling med riociguat, särskilt hos patienter med riskfaktorer, såsom nyligen genomgångna episoder av allvarlig hemoptys, inklusive de som behandlats med bronkial arteriell embolisering.
the risk of serious and fatal respiratory tract bleeding may be further increased under treatment with riociguat, especially in the presence of risk factors, such as recent episodes of serious haemoptysis including those managed by bronchial arterial embolisation.

blödning i hjärtsäcken (hemoperikardium) blodpropp i lungan (lungemboli) och i blodkärlen i andra organsysten (trombotisk embolisering)
bleeding into the area surrounding the heart (haemopericardium) blood clot in the lung (pulmonary embolism) and in the vessels of other organ systems (thrombotic embolisation)

av de inkluderade patienterna hade 83,1 % angiomyolipom som var ≥4 cm (28,8 % var ≥8 cm), 78,0 % hade bilaterala angiomyolipom, 39,0 % hade genomgått tidigare embolisering/nefrektomi, 96,6 % hade hudlesioner vid studiestart och 44,1 % hade sega (minst en sega ≥1 cm i diametern).
of the enrolled patients, 83.1% had angiomyolipomas ≥4 cm (28.8% ≥8 cm), 78.0% had bilateral angiomyolipomas, and 39.0% had undergone prior renal embolisation/nephrectomy; 96.6% had skin lesions at baseline and 44.1% had target segas (at least one sega ≥1 cm in longest diameter).